PsA with concomitant active IBD are strong based on moderate-quality evidence, except for 2 conditional recommendations based on very-low-quality evidence. Active PsA in OSM-and biologic treatment-naive patients with concomitant active IBD. In patients with active PsA with concomitant active IBD who have not received OSM or biologic treatment, a monoclonal antibody TNFi biologic (excludes etanercept, which is a fusion molecule/soluble receptor biologic) is recommended over an OSM (Table 5